Document is current
Any future updates will be listed below
-
Authors
Stertman, Erik
Gabro, Fade
Sandstedt, Mårten
Sysoev, Oleg
Lauermann, Jörg
Östgren, Carl Johan
Lawesson, Sofia Sederholm
Engvall, Jan
Nilsson, Staffan
Iredahl, Fredrik
-
Funding
Funding for this research was provided by:
Linköping University
- License Information
-
More Information
Article History
Received: 2 February 2025
Accepted: 6 May 2025
First Online: 20 May 2025
Declarations
:
: This study was approved by the Swedish Ethical Review Authority (registration number 2022-00739-01 and 2022-05381-02) who waived the requirement of obtaining written informed consent given the retrospective study design. In line with Swedish legislation, patients were informed about their enrolment in the Swedish Web-based system for Enhancement and Development of Evidence-based care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART) registry at the time of the CCTA examination and were offered the possibility to opt out of registration []. The study was performed in accordance with the International Ethical Guidelines for Health-related Research Involving Humans (2016) [].
: Not applicable.
: F.I. has received speaker fees and served on advisory boards for Novo Nordisk, Sanofi and Boehringer Ingelheim. S.S.L. has received speaker fees from Pfizer, Bayer, Astra Zeneca, Boehringer Ingelheim and Novartis and served on advisory boards for Novartis. All other authors declare no competing interests.
: None.
